Characterization of Second Primary Malignancies in Mucosa-Associated Lymphoid Tissue Lymphomas: A SEER Database Interrogation.
- 1 February 2022
- journal article
- research article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (2) , 76-81
Abstract
No abstract availableKeywords
Funding Information
- TG Therapeutics
- National Cancer Institute
- Takeda Pharmaceutical Company
This publication has 13 references indexed in Scilit:
- Long-Term Outcomes of 107 Cases of Primary Thyroid Mucosa-Associated Lymphoid Tissue Lymphoma at a Single Medical Institution in JapanThe Journal of Clinical Endocrinology & Metabolism, 2017
- Second Primary Malignancy in Bladder Carcinoma – A Population-based StudyAnticancer Research, 2017
- Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphomaLeukemia & Lymphoma, 2017
- Molecular Pathogenesis of MALT LymphomaGastroenterology Research and Practice, 2015
- Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic siteBritish Journal of Haematology, 2014
- Risk of second malignancies in patients with gastric marginal zone lymphomas of mucosa associate lymphoid tissue (MALT)Journal of Gastroenterology, 2013
- Survival of patients with marginal zone lymphomaCancer, 2012
- Risk of Second Cancer in Nongastric Marginal Zone B-Cell Lymphomas of Mucosa-Associated Lymphoid Tissue: A Population-Based Study from Northern ItalyClinical Cancer Research, 2007
- The risk of secondary malignancies over 30 years after the treatment of non‐Hodgkin lymphomaCancer, 2006
- Incidence of second neoplasms in patients with MALT lymphoma: No increase in risk above the background populationAnnals of Oncology, 1999